BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

998 related articles for article (PubMed ID: 30246298)

  • 1. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
    Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
    Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A developed antibody-drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line.
    Abdollahpour-Alitappeh M; Hashemi Karouei SM; Lotfinia M; Amanzadeh A; Habibi-Anbouhi M
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1-8. PubMed ID: 29523024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
    Li H; Yu C; Jiang J; Huang C; Yao X; Xu Q; Yu F; Lou L; Fang J
    Cancer Biol Ther; 2016 Apr; 17(4):346-54. PubMed ID: 26853765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells.
    Serwotka-Suszczak AM; Sochaj-Gregorczyk AM; Pieczykolan J; Krowarsch D; Jelen F; Otlewski J
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
    Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H
    Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
    Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J
    MAbs; 2021; 13(1):1914885. PubMed ID: 33904380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-drug conjugates with HER2-targeting antibodies from synthetic antibody libraries are highly potent against HER2-positive human gastric tumor in xenograft models.
    Kuo WY; Hsu HJ; Wu CY; Chen HS; Chou YC; Tsou YL; Peng HP; Jian JW; Yu CM; Chiu YK; Chen IC; Tung CP; Hsiao M; Lin CL; Wang YA; Wang AH; Yang AS
    MAbs; 2019 Jan; 11(1):153-165. PubMed ID: 30365359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
    Francisco JA; Cerveny CG; Meyer DL; Mixan BJ; Klussman K; Chace DF; Rejniak SX; Gordon KA; DeBlanc R; Toki BE; Law CL; Doronina SO; Siegall CB; Senter PD; Wahl AF
    Blood; 2003 Aug; 102(4):1458-65. PubMed ID: 12714494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Platinum(II)-Based Bifunctional ADC Linker Benchmarked Using 89Zr-Desferal and Auristatin F-Conjugated Trastuzumab.
    Sijbrandi NJ; Merkul E; Muns JA; Waalboer DC; Adamzek K; Bolijn M; Montserrat V; Somsen GW; Haselberg R; Steverink PJ; Houthoff HJ; van Dongen GA
    Cancer Res; 2017 Jan; 77(2):257-267. PubMed ID: 27872093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity.
    Shafiee S; Mirzaei R; Salehi M; Jalili N; Taheri A; Farahmand L
    Iran J Immunol; 2023 Sep; 20(3):303-315. PubMed ID: 37434357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Quantitative Relationship Between Target Expression and Antibody-Drug Conjugate Exposure Inside Cancer Cells.
    Sharma S; Li Z; Bussing D; Shah DK
    Drug Metab Dispos; 2020 May; 48(5):368-377. PubMed ID: 32086295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
    Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N
    Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.
    Li ZH; Zhang Q; Wang HB; Zhang YN; Ding D; Pan LQ; Miao D; Xu S; Zhang C; Luo PH; Naranmandura H; Chen SQ
    Invest New Drugs; 2014 Feb; 32(1):75-86. PubMed ID: 23903896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.